Skip to Content
Morningstar

Bio-Rad Laboratories Inc Class A BIO

Morningstar Rating
Unlock
Stock XNYS Rating as of
$281.97 +2.14 (0.76%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Bio-Rad: Initiating Coverage With Wide Moat Rating and $430 Fair Value Estimate; Shares Undervalued

Jay Lee

We initiate coverage of Bio-Rad with a wide moat rating and $430 fair value estimate. We think the company is an attractive long-term investment with significant margin expansion opportunities in its consolidated businesses. Although the company’s profit margins have historically lagged peers, we think the market does not sufficiently appreciate Bio-Rad's progress and momentum in improving its cost structure.

Read Full Report

Price vs Fair Value

View History
BIO is trading at a 34% discount.
Price
$281.97
Fair Value
$422.00
Uncertainty
High
1-Star Price
$217.30
5-Star Price
$723.00
Economic Moat
Qhb
Capital Allocation
Hwtwfdyt

Bulls Say, Bears Say

Bulls

Bio-Rad is a leader in niche areas including quality controls, antigens, and digital PCR, and it has a strong razor-and-blade model in clinical diagnostics.

Bears

Bio-Rad’s consolidated businesses operate in markets with growth rates that are on the lower end of the life sciences industry.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIO is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$279.83
Day Range
$280.00–284.88
52-Week Range
$261.59–431.79
Bid/Ask
$265.80 / $293.00
Market Cap
$8.04 Bil
Volume/Avg
207,587 / 213,066

Key Statistics

Price/Earnings (Normalized)
23.54
Price/Sales
3.08
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
5.37%

Company Profile

Bio-Rad Laboratories Inc manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. It operates in two industry segments; In Clinical Diagnostics segment, the company manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In Life Sciences segment, the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with majority of the revenue being generated from United States, it also has its presence in Europe, Asia, Canada and other regions.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
8,030
Website
https://www.bio-rad.com

Competitors

Valuation

View More
Metric
BIO
TMO
DHR
Price/Earnings (Normalized)
 23.5426.4730.62
Price/Book Value
 0.924.803.43
Price/Sales
 3.085.218.20
Price/Cash Flow
 10.2025.5327.90
Price/Earnings
BIO
TMO
DHR

Financial Strength

Metric
BIO
TMO
DHR
Quick Ratio
 4.011.191.34
Current Ratio
 5.831.701.85
Interest Coverage
 −18.244.8315.85
Quick Ratio
BIO
TMO
DHR

Profitability

Metric
BIO
TMO
DHR
Return on Assets (Normalized)
 2.73%8.69%5.15%
Return on Equity (Normalized)
 3.84%18.71%8.40%
Return on Invested Capital (Normalized)
 2.95%10.97%6.02%
Return on Assets
BIO
TMO
DHR
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Medical Devices Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesQrkhznnKtrlkw$183.8 Bil
SYK
Stryker CorpGvfksjbvqjSkk$124.0 Bil
MDT
Medtronic PLCZpxfjjhvyWxqwfd$108.6 Bil
BSX
Boston Scientific CorpCplvtwmqtFhkzmw$107.1 Bil
DXCM
DexCom IncTdxslbwlVqvf$51.3 Bil
EW
Edwards Lifesciences CorpCrpztdmlHfnnr$51.3 Bil
ZBH
Zimmer Biomet Holdings IncSfkzgqwmzGmnfg$24.8 Bil
PHG
Koninklijke Philips NV ADRWtzczqhsvXqbtb$24.4 Bil
ALGN
Align Technology IncQgtpqpygJwygwsp$21.7 Bil
PODD
Insulet CorpPwwsctynFcvtw$12.4 Bil

Sponsor Center